ASM-GLOBAL
27.4.2022 19:07:08 CEST | Business Wire | Press release
ASM Global, the world’s leading producer of entertainment experiences, venue management and event strategy, has announced a $63 million plan beginning this summer to transform the AO Arena in Manchester. This plan is set to dramatically enhance the venue’s premier position for live entertainment experiences through state-of-the-art infrastructure expansion and innovative guest features as the iconic arena looks to the future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220427005883/en/
AO Arena in Manchester, located in the heart of the city, is one of the busiest indoor arenas in the world. Through its near 30-year history, the venue has firmly established itself as a beloved and iconic Manchester landmark, a must-play for artists, and a fan-favorite destination for world-class live entertainment. Officials from the AO Arena will be releasing more detailed plans in coming months.
Chris Bray, EVP Europe at ASM Global, said, “AO Arena is one of the world’s iconic venues and a much-loved part of Manchester’s rich culture and history. It has been delivering world-class entertainment experiences for over two decades. As we approach our 30th anniversary, this ambitious endeavor will not only reinforce its position as a leading destination for live entertainment but will extend its market leadership for ‘live’ and fan experiences for the next 30 years. We’re proud to be further investing into the heart of Manchester.
“The first phase will enhance and increase our standing floor capacity to share this historic arena with even more of our guests, and we will also be adding new hospitality lounges and investing in delivering an upgraded concourse experience. Our performers will be immersed in an all-new, back-of-house artists’ campus, unparalleled anywhere.”
Additional major developments include new arena entrances welcoming guests to the venue and new premium seating, which will transform the venue to an elevated experience.
AO Arena’s back-of-house campus dramatic upgrade will include a complete overhaul of the backstage experience for artists, production and crew. This includes new artist dressing rooms and production areas, a world-class green room with meet-and-greet facilities, an overhaul of crew catering, and first-class connectivity and technology.
Plans have already been jump started by the venue’s rapid scheduling of major sell-out 2022 events, including Billie Eilish, Dua Lipa, Diana Ross, Alicia Keys, Swedish House Mafia, Snoop Dogg, George Ezra and more.
Jen Mitchell, general manager at the AO Arena, said, “This is a really exciting time for AO Arena. Not only are we able to welcome guests back after a challenging two years with a program packed full of world-class acts and entertainment, now we can reveal the first phase of ASM Global’s plans for the arena’s redevelopment. This will enhance the experience for everyone who sets foot in the venue, including artists, production, crew and our staff who work so hard to make the magic happen right here in Manchester.”
Unveiled in 1995, the arena was the first indoor venue in the U.K. to be built with a layout of 360-degree seating. Attracting over 1 million visitors yearly, the 21,000-capacity arena is a winner of the Stadium Business Awards’ prestigious ‘Venue of the Year’ award. There has been a host of musical talent that has performed at the venue, from Led Zeppelin legends Jimmy Page and Robert Plant, The Rolling Stones and Pavarotti to Dua Lipa and Lady Gaga as well as Manchester’s homegrown artists including Take That, Oasis, Elbow, New Order and The Courteeners. The venue has hosted everything from the 2002 Commonwealth Games, 2008 FINA World Swimming Championships and international boxing bouts by Mike Tyson, Anthony Joshua, Tyson Fury, David Haye, Joe Calzaghe and local champions Ricky Hatton, Amir Khan and Anthony Crolla.
About ASM Global
ASM Global is the world’s leading producer of entertainment experiences. It is the global leader in venue and event strategy and management—delivering locally tailored solutions and cutting-edge technologies to achieve maximum results for venue owners. The company’s elite venue network spans five continents, with a portfolio of more than 350 of the world’s most prestigious arenas, stadiums, convention and exhibition centers, and performing arts venues. Connect with us on LinkedIn , Facebook , Instagram and Twitter . asmglobal.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005883/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom